or heart disease, or diabetes, or aids???? if so i suggest you go to geron,s website and listen to the presentation at the rodmen and renshaw symposium today !you might be surprised at how close we are to curing ALL of those diseases ! will take 20 minutes to listen...sorry, did not post this under my "investment idea" thread, as this might be too important to be overlooked !i.e. there are many trials going on now that might be of benifit to you or someone you know. as i have mentioned, i have been following this co. for many years. most of thier ip is coming to fruition. i think it would be a shame for somebody to die of cancer when the POSSIBLE cure is around the corner, and that those afflicted could be part of the trials ! if you take the time to listen, be aware it is very technical, and confusing, but you will understand the awesome potential of the science !!! if you listen, please respond here, i feel like i,m pissing into the wind ! p.s. shamrock, they also talk a lot about spinal chord injury.. however, the current fda has pushed human trials back another 6 months .. politics !!!
anyone you know have cancer ??
- Thread starter new redneck
- Start date
p.s.
p.s.
if you think i am shitting you, check out the volume on gern today !! eddie haskell, this co is for real !!!!!!
p.s.
if you think i am shitting you, check out the volume on gern today !! eddie haskell, this co is for real !!!!!!
Redneck, I recently went to a huge symposium in Boston with many of the countries leading stem cell scientists, along with many ethic lawyers in this arena. I personally talked with Stanford University leading stem cell doctor, who was really saying good things about Geron. With today s Democratic victory in house & Senate, shortly scientists hands won't be handcuffed regarding stem cell study.
shamrock
shamrock
mixed emotions for me today... being a republican/ libertarian, i was hoping to at least hold the senate...being heavily invested in geron, and believing they hold the keys to the future of medicine, i was not upset to know that soon we will have gov funding of esc research.. the key point is that geron does not need gov funding !! listen to the presentation today !!!!p.s. as you now are finding out, ALL embryonic stem cell innovators will have to pay royalties to gern !!!! email me sometime ! would like to talk to a pats fan ... what was up with brady ?????
shamrock
mixed emotions for me today... being a republican/ libertarian, i was hoping to at least hold the senate...being heavily invested in geron, and believing they hold the keys to the future of medicine, i was not upset to know that soon we will have gov funding of esc research.. the key point is that geron does not need gov funding !! listen to the presentation today !!!!p.s. as you now are finding out, ALL embryonic stem cell innovators will have to pay royalties to gern !!!! email me sometime ! would like to talk to a pats fan ... what was up with brady ?????
This is one of the biggest fallacies and the thing that made me most want to strangle pundits who kept perpetrating this myth.
The ban on stem cell research was using federal funds to do so. If Merck, J+J or any of the giganormous pharma companies wanted to spend a trillion dollars *tomorrow* on stem cell research they could - nothing is stopping them. All these adds that make you think so and so voted against stem cell research - they voted against using federal money to do so. I know it may seem like a small point but I dont think it is. The % of scientific spending that comes from the feds vs what the private firms have in available capital is minuscule.
Sorry, I know this stuff goes in the politics folder, just a leftover vent from the campaigning season. Thank god its over.
acehist8
acehist8
perhaps you are unaware that merck has partnerned with gern, and has bought 3 % of the co... also they have the rights to invest more.. last weeks pr. re lamp was donn to faccilitate the merk/ geron cancer vaccine program.. do your home work !!!!
acehist8
perhaps you are unaware that merck has partnerned with gern, and has bought 3 % of the co... also they have the rights to invest more.. last weeks pr. re lamp was donn to faccilitate the merk/ geron cancer vaccine program.. do your home work !!!!
If we still had the rep system I would give you positive points for the use of that word.
Dems for Stems
By Will Swarts
November 8, 2006
StemCells (STEM1)
Share price as of Tuesday's close: $3.07
Share price now: $3.39
Percent change: 10.4%
Volume: 16.4 million shares, daily average 1.4 million
The News
Missourians narrowly approved a ballot measure that encourages stem-cell research in their state on Tuesday, prompting investors to vote with their wallets. Shares of a basket of biotechnology companies specializing in stem cells rose on Wednesday.
A chief beneficiary of the "Missouri Stem Cell Research and Cures Initiative2" was StemCells (STEM3), whose shares popped 10% on the referendum's slim 51%-49% margin of victory. The initiative ensures access to federally permitted stem-cell research for scientists, doctors and patients in the state. Other shares enjoying a bump included those of Geron (GERN4), one of the largest and best-known stem-cell research operations, Aastrom Biosciences (ASTM5) and Cytori Therapeutics (CYTX6).
None of the stem-cell companies is profitable, and all their stocks are down for the year to date. But as stem-cell research assumed a larger role in the Missouri campaign, many of these stocks enjoyed healthy run-ups as investors bet on changes surrounding a hot-button issue. The state issue received national attention after conservative talk radio host Rush Limbaugh ridiculed an endorsement for Democratic senatorial candidate Claire McCaskill that featured the actor Michael J. Fox, who suffers from Parkinson's disease. In the political commercial, Fox trembles visibly; Limbaugh claimed the actor was exaggerating his symptoms.
McCaskill narrowly edged incumbent Republican Jim Talent in the Senate race.
But far away from the Show Me State, stem-cell research companies notched a short-term win for their stock prices. That likely won't last, say industry watchers, because the external issues have no bearing on these companies' fundamental performance. Similar measures in New Jersey and California prompted similar price moves several years ago.
But looking ahead, the Missouri initiative changes the playing field for an area of scientific research that's been inhibited by federal legislation. Until the Senate voted July 18 to reverse President Bush's ban on research on embryonic stem-cell lines created before 2001, ongoing research was hobbled and was unable to find connections to larger industrial partners that could create commercial applications for treating diseases, says Steve Brozak, an analyst at WBB Securities in San Diego.
"There's been a visible absence of large pharmaceuticals and large biotech in the field," he says. "So what you've got is a situation where there's been a stultifying effect on all these independent researchers."
The Analysis
No company was better poised for a one-day lift than Palo Alto, Calif.-based StemCells, observes Jose Haresco, an analyst at Merriman Curhan Ford & Co. It's equally vulnerable to a bit of a drop-off once the buzz fades, largely because it's heavily owned by retail investors, who are more volatile in their buying and selling than large institutional investors.
"It's the perfect ticker," he says. "It swings wildly on anything that affects it politically, but fundamentally that doesn't affect the company at all."
Brozak, who doesn't cover StemCells, concurs, and says he's not sure lots of these short-term players even fit the mold of typical biotech investors, who must have a high risk tolerance for the volatile sector.
"Look at the symbol: Do you think the people who are investing today really have a clue about what they're investing in?" he says. "They are sitting and watching CNBC, and sitting by computers and day trading."
That's not to dismiss the company's real efforts. StemCells last year was cleared by the Food and Drug Administration to begin a Phase I trial on a treatment based on neural stem cells for Batten disease, a fatal neurodegenerative disorder. The disease is caused by genetic mutations that result in a defective or missing enzyme. Batten patients, who are often diagnosed as young children, experience mental impairment, seizures, sight loss and declining motor skills. Eventually, patients become blind, bedridden and unable to communicate. Few survive past their early 20s, according to the Batten Disease Support and Research Association.
The Bottom Line
The electoral effect on these stocks won't last, but the signal Missouri sent to the stem-cell research sector and to investors looking for opportunities is clear nevertheless.
"These stocks are volatile, and they face a drop every time something bad happens" on the legislative front, Haresco says. "They should find a new level of support given the new political climate."
While the single state endorsement of stem-cell research in principle isn't grounds to expect hyper-advanced genetic tinkering and the unveiling of cures for hereditary diseases in the next few weeks, Broszak says a wider shift in regulatory attitudes is likely.
"This is the first hole in the dike," he says, "and it's saying that there is not a valid reason for this research not to take place ? in several locations."
Links in this article:
1http://www.smartmoney.com/eqsnaps/index.cfm?story=snapshot&symbol=STEM
2http://www.sos.mo.gov/elections/2006petitions/ppStemCell.asp
3http://www.smartmoney.com/cfscripts/Director.cfm?searchString=STEM
4http://www.smartmoney.com/cfscripts/Director.cfm?searchString=GERN
5http://www.smartmoney.com/cfscripts/Director.cfm?searchString=ASTM
6http://www.smartmoney.com/cfscripts/Director.cfm?searchString=CYTX
URL for this article:
http://www.smartmoney.com/onedaywonder/index.cfm?story=20061108
By Will Swarts
November 8, 2006
StemCells (STEM1)
Share price as of Tuesday's close: $3.07
Share price now: $3.39
Percent change: 10.4%
Volume: 16.4 million shares, daily average 1.4 million
The News
Missourians narrowly approved a ballot measure that encourages stem-cell research in their state on Tuesday, prompting investors to vote with their wallets. Shares of a basket of biotechnology companies specializing in stem cells rose on Wednesday.
A chief beneficiary of the "Missouri Stem Cell Research and Cures Initiative2" was StemCells (STEM3), whose shares popped 10% on the referendum's slim 51%-49% margin of victory. The initiative ensures access to federally permitted stem-cell research for scientists, doctors and patients in the state. Other shares enjoying a bump included those of Geron (GERN4), one of the largest and best-known stem-cell research operations, Aastrom Biosciences (ASTM5) and Cytori Therapeutics (CYTX6).
None of the stem-cell companies is profitable, and all their stocks are down for the year to date. But as stem-cell research assumed a larger role in the Missouri campaign, many of these stocks enjoyed healthy run-ups as investors bet on changes surrounding a hot-button issue. The state issue received national attention after conservative talk radio host Rush Limbaugh ridiculed an endorsement for Democratic senatorial candidate Claire McCaskill that featured the actor Michael J. Fox, who suffers from Parkinson's disease. In the political commercial, Fox trembles visibly; Limbaugh claimed the actor was exaggerating his symptoms.
McCaskill narrowly edged incumbent Republican Jim Talent in the Senate race.
But far away from the Show Me State, stem-cell research companies notched a short-term win for their stock prices. That likely won't last, say industry watchers, because the external issues have no bearing on these companies' fundamental performance. Similar measures in New Jersey and California prompted similar price moves several years ago.
But looking ahead, the Missouri initiative changes the playing field for an area of scientific research that's been inhibited by federal legislation. Until the Senate voted July 18 to reverse President Bush's ban on research on embryonic stem-cell lines created before 2001, ongoing research was hobbled and was unable to find connections to larger industrial partners that could create commercial applications for treating diseases, says Steve Brozak, an analyst at WBB Securities in San Diego.
"There's been a visible absence of large pharmaceuticals and large biotech in the field," he says. "So what you've got is a situation where there's been a stultifying effect on all these independent researchers."
The Analysis
No company was better poised for a one-day lift than Palo Alto, Calif.-based StemCells, observes Jose Haresco, an analyst at Merriman Curhan Ford & Co. It's equally vulnerable to a bit of a drop-off once the buzz fades, largely because it's heavily owned by retail investors, who are more volatile in their buying and selling than large institutional investors.
"It's the perfect ticker," he says. "It swings wildly on anything that affects it politically, but fundamentally that doesn't affect the company at all."
Brozak, who doesn't cover StemCells, concurs, and says he's not sure lots of these short-term players even fit the mold of typical biotech investors, who must have a high risk tolerance for the volatile sector.
"Look at the symbol: Do you think the people who are investing today really have a clue about what they're investing in?" he says. "They are sitting and watching CNBC, and sitting by computers and day trading."
That's not to dismiss the company's real efforts. StemCells last year was cleared by the Food and Drug Administration to begin a Phase I trial on a treatment based on neural stem cells for Batten disease, a fatal neurodegenerative disorder. The disease is caused by genetic mutations that result in a defective or missing enzyme. Batten patients, who are often diagnosed as young children, experience mental impairment, seizures, sight loss and declining motor skills. Eventually, patients become blind, bedridden and unable to communicate. Few survive past their early 20s, according to the Batten Disease Support and Research Association.
The Bottom Line
The electoral effect on these stocks won't last, but the signal Missouri sent to the stem-cell research sector and to investors looking for opportunities is clear nevertheless.
"These stocks are volatile, and they face a drop every time something bad happens" on the legislative front, Haresco says. "They should find a new level of support given the new political climate."
While the single state endorsement of stem-cell research in principle isn't grounds to expect hyper-advanced genetic tinkering and the unveiling of cures for hereditary diseases in the next few weeks, Broszak says a wider shift in regulatory attitudes is likely.
"This is the first hole in the dike," he says, "and it's saying that there is not a valid reason for this research not to take place ? in several locations."
Links in this article:
1http://www.smartmoney.com/eqsnaps/index.cfm?story=snapshot&symbol=STEM
2http://www.sos.mo.gov/elections/2006petitions/ppStemCell.asp
3http://www.smartmoney.com/cfscripts/Director.cfm?searchString=STEM
4http://www.smartmoney.com/cfscripts/Director.cfm?searchString=GERN
5http://www.smartmoney.com/cfscripts/Director.cfm?searchString=ASTM
6http://www.smartmoney.com/cfscripts/Director.cfm?searchString=CYTX
URL for this article:
http://www.smartmoney.com/onedaywonder/index.cfm?story=20061108
ace, it is NOT EXCLUSIVELY about federal funding. Several states, in fact the majority still have criminal legislation against scientist doing stem cell research in those states. Presently only 6 states, 7 today with Missouri, will even allow private funded study. The ignorance on this subject is unbelievable.
I'm sorry but NO states to my knowledge nor anything I have read (which is a lot for family reasons) says that there is any state that bans any and all kinds of stem cell research or has criminal legislation on the books banning all kinds of SSL. If you can show me one I will stand corrected. To clarify your clarification, most if not all states allow privately funded stem cell research. Those seven state laws you refer to deal with embryonic stem cell research, not stem cell research in general, and yes there is a big difference. State statutes for the most part (AZ, NB, used to be Missouri) are in place to prohibit state funds from being used in these cases. Indiana for example banned human cloning to generate embryonic stem cells but created a facility and fully allows all other stem cell research
The National Conference of State Legislators has a pretty good analysis of this, obviously not updated since last night:
http://www.ncsl.org/programs/health/genetics/embfet.htm
KUMC map of states supporting research, as shown, 7 currently supporting embryonic or "early" SSR:
http://www.kumc.edu/stemcell/statepublicpolicy.html
As you can see 14 states have various restrictions most of which involve the prohibition of work on discarded embryos or fetuses:
http://www.fas.org/spp/civil/crs/RL31015.pdf
My point more was that, if Merck went to Missouri and said, heres $50B we want to build the biggest privately funded stem cell facility in the world, they could.
And I'm sorry but as for stock picks, I'm not into pimping out junk stock companies no matter what the cause, I get enough of those junk emails every day as it is sorry.
The National Conference of State Legislators has a pretty good analysis of this, obviously not updated since last night:
http://www.ncsl.org/programs/health/genetics/embfet.htm
KUMC map of states supporting research, as shown, 7 currently supporting embryonic or "early" SSR:
http://www.kumc.edu/stemcell/statepublicpolicy.html
As you can see 14 states have various restrictions most of which involve the prohibition of work on discarded embryos or fetuses:
http://www.fas.org/spp/civil/crs/RL31015.pdf
My point more was that, if Merck went to Missouri and said, heres $50B we want to build the biggest privately funded stem cell facility in the world, they could.
And I'm sorry but as for stock picks, I'm not into pimping out junk stock companies no matter what the cause, I get enough of those junk emails every day as it is sorry.
Last edited:
ace
ace
for a lot less than 50 billion merck could buy gern, lock stock and barrel/ however, as the ceo has stated, that will never happen, " we are big bad and ugly" the next amgen !!!!plus, merck, and geron are already partners.. also png, dow. roache [sp?]uof edinbourough, and others... sorry for the spelling, shot 79 today, long cocktail hour !!!!
ace
for a lot less than 50 billion merck could buy gern, lock stock and barrel/ however, as the ceo has stated, that will never happen, " we are big bad and ugly" the next amgen !!!!plus, merck, and geron are already partners.. also png, dow. roache [sp?]uof edinbourough, and others... sorry for the spelling, shot 79 today, long cocktail hour !!!!
ace, you are 100 percent correct, I assumed we were speaking of embryonic stem cell research, because that is what the company Geron is working with. That's what the thread initially was talking about Geron, so I assumed we were speaking of embryonic stem cells, but you are correct, there are also ADULT, AND UMBILICAL STEM CELLS, which most if not all states allow research of.
Embryonic however is a different story, South Dakota for instance, a scientist could be charged same as felony murder. And that was told to me just October 22nd at a convention in Boston by a lawyer specializing on Ethics regarding stem cell research.
Sorry for the confusion, I shouldn't have assumed we were speaking of exclusively embryonic cells.
Patriots were disappointing Sunday huh? Harrison gone for 6 weeks minimum:sadwave:
Embryonic however is a different story, South Dakota for instance, a scientist could be charged same as felony murder. And that was told to me just October 22nd at a convention in Boston by a lawyer specializing on Ethics regarding stem cell research.
Sorry for the confusion, I shouldn't have assumed we were speaking of exclusively embryonic cells.
Patriots were disappointing Sunday huh? Harrison gone for 6 weeks minimum:sadwave:
I know for a fact that if a cure for Cancer and AIDS are found, the first thing that will cross my mind is my portfolio. :shrug: :shrug:
:sadwave: :sadwave:
:sadwave: :sadwave:
This is from Briefing.com this morning.
7:30AM Geron presents early clinical data for its cancer drug (GERN) 8.39 : Co announces the presentation of the first clinical trial data for its telomerase inhibitor cancer drug, GRN163L. The data demonstrate the safety, tolerability and predicted pharmacokinetics in low-dose cohorts from a Phase I/II trial in patients with chronic lymphocytic leukemia (CLL) and a Phase I trial in patients with solid tumors. "The early clinical data are very encouraging... This is the first time telomerase inhibition has been tested in cancer patients. The excellent tolerability and pharmacokinetics observed so far enable us to advance to the therapeutic dose cohorts, where we hope to demonstrate safe, sustained telomerase inhibition in the targeted tumor cells."
7:30AM Geron presents early clinical data for its cancer drug (GERN) 8.39 : Co announces the presentation of the first clinical trial data for its telomerase inhibitor cancer drug, GRN163L. The data demonstrate the safety, tolerability and predicted pharmacokinetics in low-dose cohorts from a Phase I/II trial in patients with chronic lymphocytic leukemia (CLL) and a Phase I trial in patients with solid tumors. "The early clinical data are very encouraging... This is the first time telomerase inhibition has been tested in cancer patients. The excellent tolerability and pharmacokinetics observed so far enable us to advance to the therapeutic dose cohorts, where we hope to demonstrate safe, sustained telomerase inhibition in the targeted tumor cells."
unfortunately, cancer is rampant in my area. I currently have 3 co-workers with active cancer being treated (only 100 employees in my department), and I know many more in the community. I hope this company is on to something.
Six
I also am very close to some people with active cancer.
but I think we have a "very bright light bulb" here.
We'll see.
I'm calling it, "This forums Tom Vu"
six five..intense
six five..intense
maybe some of these people you know could get onto a trial.. the one in chicago is for all tumors !!! info on website... glad to see a few of you took the time to look... inho, you will be well rewarded in the future !!understand, investing in biotesh requires patience ! my guess is within 2 years... best to y,all.....
six five..intense
maybe some of these people you know could get onto a trial.. the one in chicago is for all tumors !!! info on website... glad to see a few of you took the time to look... inho, you will be well rewarded in the future !!understand, investing in biotesh requires patience ! my guess is within 2 years... best to y,all.....
sorry for the typo,s !!!!
sorry for the typo,s !!!!
played for beers today and won !no way i was not going to collect... madjack, nice buy !!!
sorry for the typo,s !!!!
played for beers today and won !no way i was not going to collect... madjack, nice buy !!!
